Applied Therapeutics (APLT) Expected to Announce Earnings on Wednesday

Applied Therapeutics (NASDAQ:APLT) is expected to be releasing its earnings data before the market opens on Wednesday, March 5th. Analysts expect Applied Therapeutics to post earnings of ($0.15) per share and revenue of $0.10 million for the quarter.

Applied Therapeutics Stock Performance

NASDAQ:APLT opened at $0.46 on Tuesday. The firm has a market capitalization of $53.38 million, a PE ratio of -0.28 and a beta of 1.88. The stock’s fifty day moving average is $0.66 and its 200 day moving average is $4.52. Applied Therapeutics has a fifty-two week low of $0.46 and a fifty-two week high of $10.62.

Wall Street Analysts Forecast Growth

APLT has been the topic of several recent analyst reports. William Blair downgraded shares of Applied Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, December 23rd. UBS Group reissued a “neutral” rating and issued a $2.00 price objective (down from $13.00) on shares of Applied Therapeutics in a research report on Monday, December 2nd. Robert W. Baird decreased their price objective on shares of Applied Therapeutics from $14.00 to $5.00 and set an “outperform” rating for the company in a research note on Friday, November 29th. Citigroup cut their target price on Applied Therapeutics from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 29th. Finally, Royal Bank of Canada decreased their price target on Applied Therapeutics from $4.00 to $1.50 and set a “sector perform” rating for the company in a research note on Friday, December 20th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.10.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.